Arterial vessels express one or more heme oxygenase (HO) isoenzymes that catalyze the metabolism of heme to carbon monoxide (CO) and biliverdin. Carbon monoxide promotes vasorelaxation through mechanisms that, depending on the vessels, involve activation of soluble guanylate cyclase, stimulation of calcium-activated potassium channels, or diminished synthesis of constrictor mediators, such as, endothelin and 20-HETE. Inhibitors of HO elicit vasoconstriction in vivo and in isolated pressurized arterioles. Inhibitors of HO also enhance myogenic vasoconstriction, as well as the constriction induced by phenylephrine in several vessels. The blood pressure of awake rats is increased by acute treatment with HO inhibitors, a response that is accompanied by attenuation of baroreflex activity. All in all, it would appear that a product of HO activity manufactured by arterial vessels, presumably CO, promotes vasodilation and decreases the reactivity of vascular smooth muscle to myogenic stimuli and constrictor agonists. In doing so, CO of vascular origin may contribute to the implementation of antihypertensive mechanisms. Carbon monoxide produced in central nervous system structures, for example, the nucleus tractus solitarii, also appears to support a blood pressure-lowering mechanism linked to inhibitory modulation of baroreceptor reflex activity. Am J Hypertens 2001;14:62S-67S
H
eme is a metalloporphyrin (ferroporphyrin IX) that serves as the prosthetic group of proteins involved in crucial biological events such as oxygen transport, mitochondrial respiration, processing of reactive oxygen species, drug metabolism, and the manufacture of biologically active substances. 1, 2 The pathways of heme biosynthesis and degradation in eukaryotes are ubiquitous.
1,2 Cellular heme undergoes oxidative metabolism by heme oxygenase (HO) yielding equimolar quantities of biliverdin, ferrous iron, and carbon monoxide (CO).
1,2 Three HO isoforms have been characterized: HO-1, HO-2, and HO-3.
1,3 HO-1 is induced by many different factors and conditions that share in the ability to produce oxidative stress.
1,2 HO-2 is constitutively expressed in virtually all tissues and is not subject to induction by agents or conditions that enhance HO-1 expression. 1 HO-3 is expressed constitutively, like HO-2, but its heme degrading activity is low. 3 During the past several years there has been an outpouring of reports attributing diverse biological activities to the products of heme metabolism by HO. For example, reactive iron released from heme during its degradation by HO is a prooxidant. 4 In contrast, biliverdin and its reduced derivative bilirubin display antioxidant properties 4 and when produced in excess, as a result of HO-1 induction, are believed to confer protection against oxidative stress. 4 Carbon monoxide stimulates potassium channel activity in smooth muscle, 5 and binds to heme-containing enzymes affecting their activity. 1 For example, CO enhances the activity of soluble guanylate cyclase, 1 but decreases the activity of nitric oxide synthase 6 and of cytochrome P450 oxygenase. 7 Marks and co-workers 8 suggested in 1991 that endogenous CO participates in the regulation of cell function and communication. Subsequently, evidence was presented that CO arising from heme through metabolism by HO regulates cyclic GMP production in the brain and vascular tissues, 1, 9 and that experimental manipulation of HO impacts on vascular function and the level of blood pressure. 9, 10 This article examines the evidence that a heme-HO system intrinsic to arterial vessels contributes to the regulation of vascular tone and reactivity by the generation of CO.
The Vascular Heme-Ho System
Several lines of evidence document the presence of an active heme-heme oxygenase system in vascular tissues. Northern blot analysis of RNA prepared from rat aorta demonstrated the presence of mRNAs coding for HO-1 and HO-2. 11, 12 Immunohistochemical studies revealed staining for HO-1 in the smooth muscle and adventitia of rat aorta, 11, 12 in the endothelium and smooth muscle of the lamb ductus arteriosus, 13 and in the media and adventitia of bovine pulmonary artery.
14 Immunostaining for HO-2 was demonstrated in the endothelium and smooth muscle of rat aorta, 11 in the smooth muscle of the lamb ductus arteriosus, 13 and in the endothelium, media, and adventitia of bovine pulmonary artery.
14 Western blot analysis of vascular proteins documented presence of HO-2 protein in the aorta, 11, 13 renal interlobar artery, 15 and gracilis muscle arterioles 16 of rat, in lamb ductus arteriosus, aorta and pulmonary artery, 13 and in cerebral arteries of newborn pigs. 17 HO-1 protein was detected in the aorta of normal rats in some studies, 11 but not in others 8 ; the expression of HO-1 in aorta was increased in rats made hypertensive by angiotensin II infusion 11 and in rats subjected to surgical stress. 18 HO-1 protein was not detected in renal arteries and gracilis muscle arterioles of rats or in cerebral arteries of newborn pigs. 16, 17 Cultured vascular smooth muscle cells express HO-1 and HO-2.
19 HO-1 expression in smooth muscle is increased by heme, heavy metals, cytokines, hydrogen peroxide, nitric oxide, agents that promote generation of cAMP, hypoxia, or increased sheer stress. 9 None of the conditions affecting HO-1 expression were found to alter the expression of HO-2 in vascular smooth muscle cells. HO-1 also is expressed in cultured endothelial cells, and the expression is upregulated by nitric oxide, heme, peroxynitrite, tumor necrosis factor-␣, and interleukin-1␣. 9 Heme oxygenase expressed by vascular tissues is catalytically active, as inferred from observations that exogenous heme is metabolized to biliverdin and CO during in vitro incubation with homogenates of conduit arteries. 11, 13, 14 Also, as shown in Fig. 1 , vascular segments release CO (measured by gas chromatography-mass spectroscopy) into the headspace gas during ex vivo incubation in Krebs' buffer. Treatment of the vessels with chromium mesoporphyrin (CrMP, 15 mol/L), a competitive inhibitor of HO, greatly reduced the amount of CO released into the headspace gas. This is consistent with the notion that the CO released from intact arterial vessels is newly manufactured by vascular HO. We observed HO-dependent release of CO in the aorta, renal interlobar artery, middle cerebral artery, and gracilis muscle arterioles of rat. Of note, the amount of CO release from the rat aorta is exceeded by that released from smaller vessels.
All in all, the preceding discussion supports the notion that vascular tissues are endowed with active HO that generates CO and biliverdin from heme. Most of the evidence suggest that in "normal" vascular tissues the expression of HO-2 is more prominent than that of HO-1, whereas in stressful settings the latter enzyme becomes dominant.
Vasoregulatory Actions of Exogenous CO
Carbon monoxide relaxes rabbit 20, 21 and rat 22 aorta, dog coronary artery, 20 rabbit pulmonary artery, 23 lamb ductus arteriosus, 24 and rat tail arteries. 25 However, CO was shown not to relax rabbit basilar and middle cerebral arteries and dog basilar artery. 26 In general, as judged by the aforementioned reports, the potency of exogenous CO in eliciting relaxation of conduit and middle caliber arteries is unimpressive.
Several studies have documented the ability of exogenous CO to dilate resistance vessels. However, reports on the vasodilatory potency of CO are quite variable. The internal diameter of blood-perfused rat renal afferent arterioles in vitro is increased by exposure to CO at 0.1 and 1.0 mol/L. 6 Interesting, at higher concentrations CO was reported not to dilate rat renal afferent arterioles. 6 In newborn pigs, CO increases the diameter of small pial arterioles in concentrations as low as 10 Ϫ10 mol/L. 17 Carbon monoxide also increases the diameter of pressurized rat gracilis muscle arterioles, 27 and this action is amplified in preparations pretreated with a heme oxygenase inhibitor. 16 Bearing on this observation, CO was reported to reduce vascular resistance in isolated rat livers perfused with media containing an inhibitor of HO but not in livers perfused with control media. 28 Hence, the endogenous production of CO may be one of the factors affecting the 
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responsiveness of vascular smooth muscle to an exogenous source of this gas. The relaxing action of CO in large arteries is endothelium independent 20 -22 and not a consequence of tissue hypoxia. 22 Carbon monoxide binds to the heme moiety of soluble guanylate cyclase and causes its activation. 1 In rabbit aorta, the relaxing action of CO is linked to guanylate cyclase, as it is accompanied by augmentation of tissue cGMP levels and is virtually eliminated by inhibitors of guanylate cyclase. 20, 21 On the other hand, inhibitors of guanylate cyclase only attenuated partially the relaxing action of CO in the lamb ductus arteriosus 24 and rat tail artery. 25 The cGMP-independent component of the relaxing response to CO was ascribed to a cytochrome P450-and endothelin-dependent mechanisms in the lamb ductus arteriosus, 13 and to stimulation of big conductance calcium-activated potassium channels in the smooth muscle of the rat tail artery. 5 The dilatory effect of CO in pial arterioles of the newborn pig was blocked by tetraethylammonium and iberiotoxin and, consequently, also was attributed to activation of calcium-activated potassium channels.
17 Surprisingly, CO-induced dilation of pial arterioles in the newborn pig is blocked by pharmacologic inhibition of cyclooxygenase or nitric oxide synthase. 29 Because treatment with a prostacyclin mimetic or a nitric oxide donor restores dilatory responsiveness to CO in pial arterial preparation pretreated with an inhibitor of cyclooxygenase or nitric oxide synthase, respectively, it would appear that prostacyclin and nitric oxide play a permissive role in CO-induced vasodilation. 29 Information is lacking on the mechanism underlying the regulatory influence of prostacyclin and nitric oxide on CO-induced pial arteriolar dilation. One possibility to consider is that prostacyclin and nitric oxide modulate the stimulatory action of CO on calcium-activated potassium channels.
Functional Significance of CO of Vascular Origin
Carbon monoxide produced by aortic smooth muscle cells was shown to increase the cGMP content of the cells 9, 19 and to mediate hypoxia-induced elevation of cellular cGMP. 30 In experiments coculturing vascular smooth muscle and endothelial cells, CO manufactured by smooth muscle cells decreased the expression of endothelin-1 and platelet-derived growth factor-B in endothelial cells. 31 The proliferation of hypoxic vascular smooth muscle cells was increased by interventions that decreased CO production, and was decreased by conditions that increased CO. 32 Hence, CO produced by vascular smooth muscle may be an important feature of interactions among smooth muscle and endothelial cells and impact on the production of regulatory factors influencing the tone and growth of blood vessels.
The role of endogenously produced CO in regulation of vascular tone has been addressed by examining the effect of heme-L-lysinate, an HO substrate, on the diameter of arterial vessels. The internal diameter of isolated rat gracilis muscle arterioles, pressurized and superfused with Krebs' buffer containing N -nitro-L-arginine methyl ester (L-NAME), increases when heme L-lysinate is included in the superfusion buffer. 27 Importantly, heme-induced arteriolar dilation cannot be demonstrated in vessels pretreated with a HO inhibitor, suggesting that a product of HO activity mediates the vasodilatory effect of the HO substrate. 27 As CO but not biliverdin elicits dilation of gracilis muscle arterioles, the dilatory effect of heme L-lysinate is attributable to CO generated from heme by vascular HO. 27 Heme oxygenase-dependent formation of CO also contributes to the dilatory effect of heme in pial arterioles of newborn pigs. 17 Another approach used to study the function of the vascular heme-HO system is to determine the vascular response to HO inhibition. In the lamb ductus arteriosus, 13 an HO inhibitor did not affect isometric tension in preparations exposed to 95% O 2 but caused contraction in hypoxic preparations. Heme oxygenase inhibitors were without effect on the tone of rat tail artery, 25 rat aorta, 16 and rat femoral artery. 16 In contrast, HO inhibitors markedly reduced the diameter of isolated gracilis muscle arterioles pressurized to 80 mm Hg and superfused with L-NAME-containing buffer. 16 The constrictor effect of the inhibitors in this preparation varied in relation to the level of pressurization and was prevented by inclusion of CO into the superfusion buffer. 16 Inhibition of HO also was reported to bring about vasoconstriction in vivo. For example, infusion of the HO inhibitor zinc deuteroporphyrin 2,4-bis glycol (ZnDPBG) into the renal medulla of anesthetized rats decreased medullary blood flow without affecting arterial pressure. 33 The HO inhibitor CrMP was reported to increase hindquarter vascular resistance in anesthetized rats pretreated with L-NAME. 34 Such findings may be taken as evidence that the heme-HO system exerts a tonic vasodilatory influence in the peripheral circulation.
An important aspect of the regulation of vascular tone is the dynamic interplay among myogenic and various neurohormonal mechanisms. Recent studies offer evidence linking the vascular heme-HO system to the regulation of vasoconstrictor responsiveness to myogenic and hormonal stimuli. We contrasted pressure-induced constrictor responses in isolated rat gracilis muscle arterioles superfused with Krebs' buffer containing and not containing CrMP to inhibit HO, both in the absence and the presence of L-NAME. As shown in Fig. 2 , augmentation of intraluminal pressure in 20 mm Hg steps elicited reduction of the internal arteriolar diameter (expressed as percentage of the passive diameter in the absence of calcium). Pressureinduced reductions of arteriolar diameter were magnified in preparations superfused with CrMP. Importantly, the magnifying effect of CrMP on pressure-induced arteriolar constriction was further amplified in preparations super-
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fused with buffer containing L-NAME to inhibit nitric oxide synthesis. Myogenic constrictor responses to elevation of intraluminal pressure also were reported to be increased in gracilis muscle arterioles maintained for 18 h before experimentation in media containing antisense oligodeoxynucleotides directed against HO-2 mRNA. 35 Moreover, the inclusion of authentic CO into the superfusion buffer greatly minimized the magnifying effect of HO-2 antisense treatment on pressure-induced vasoconstriction. 35 Hence, based on these observations, it would appear that CO manufactured by vascular HO is an inhibitor of myogenic vasoconstriction, particularly under conditions in which nitric oxide synthesis is impaired.
We also examined the effect of treatment with CrMP or with HO-2 antisense oligodeoxynucleotides on phenylephrine-induced constriction of rat renal interlobar arteries, isolated and mounted on a wire myograph for measurement of isometric tension. Shown in Fig. 3 , the inclusion of CrMP (30 mol/L) into the bathing buffer caused a leftward shift in the concentration-response curve to phenylephrine, decreasing the EC 50 (concentration of agonist that elicits 50% of the maximal response) without altering the maximal response. A leftward shift in the concentration-response curve to phenylephrine also was noted in renal interlobar arteries maintained in organ culture for 18 h in media containing HO-2 antisense oligodeoxynucleotides. 15 As the inclusion of authentic CO into the bathing buffer offsets the sensitizing influence of treatment with either CrMP or HO-2 antisense on constrictor responsiveness to phenylephrine, the sensitization caused by such interventions may be ascribed to inhibition of vascular CO synthesis.
If inhibition of HO activity or expression enhances the vasoconstrictor effect of phenylephrine, it is to be expected that interventions that enhance the activity or expression of vascular HO would attenuate responsiveness of vascular smooth muscle to the constrictor action of phenylephrine. Several studies support this contention. Incubation of rat tail arteries with hemin, to induce HO-1, attenuates phenylephrine-induced vascular contraction. 25 The inhibitory effect of hemin on constrictor responses to phenylephrine is offset by an HO inhibitor as well as by oxyhemoglobin, a scavenger of CO, suggesting that CO mediates the inhibitory effect of hemin. 25 Decreased constrictor responsiveness to phenylephrine also was found in aortas from hypoxic rats, 36 and in aortas incubated for several hours with a nitric oxide donor, 12 both conditions known to induce HO-1. On the basis of the aforementioned evidence, CO of vascular origin appears to subserve vasodilatory mechanisms, in part by decreasing the sensitivity of vascular smooth muscle to myogenic stimuli and constrictor agonist.
FIG. 2.
Effect of stepwise increments in intraluminal pressure on the normalized internal diameter (ID) of first order rat gracilis muscle arterioles mounted on a pressure-myograph and superfused with Krebs' buffer with and without chromium mesoporphyrin (CrMP), both in the presence and absence of N -nitro-L-arginine methyl ester (L-NAME, 1 mmol/L). The "normalized ID" is the ID expressed as a percentage of the passive ID of the vessel measured at each level of pressure during superfusion with calcium-free buffer. Results are the mean Ϯ SEM. *P Ͻ .05 relative to control.
FIG. 3.
Cumulative concentration-response curve to phenylephrine in rat renal interlobar artery rings mounted on a wire myograph and bathed in Krebs' buffer alone, buffer containing chromium mesoporphyrin (CrMP, 30 mol/L), and buffer containing both CrMP and authentic carbon monoxide (CO, 10 mol/L). Results are the mean Ϯ SEM. *P Ͻ .05 relative control. EC 50 , concentration of agonist that elicits 50% of the maximal response; R max , maximal response.
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The Heme-HO System and Blood Pressure Regulation
In 1995, it was reported that acute treatment of awake rats with an inhibitor of HO, ZnDPBG, increases blood pressure and peripheral vascular resistance by way of a mechanism that presumably involves withdrawal of the inhibitory influence of endogenous CO on sympathetically mediated pressor functions. 10 An inhibitor of HO also was reported to increase blood pressure in spontaneously hypertensive rats and Wistar-Kyoto normotensive rats, 37 and in Wistar rats on a normal but not on a high salt intake. 38 The pressor response to systemic administration of ZnD-PBG is accompanied by reduction in the gain of the baroreceptor reflex. 39 Relevant to this point, injection of an HO inhibitor into the nucleus tractus solitarii (NTS) of rats elicits a pressor response that can be reversed by ipsilateral injection of CO. 39 This is consistent with a report that baroreceptor reflex activity in rats is attenuated by the administration of ZnDPBG into the NTS. 40 Injection of ZnDPBG into the NTS also was shown to attenuate the cardiovascular response to ipsilateral injection of Lglutamate. 41 Thus, a product of HO activity in the NTS, presumably CO, may serve as an inhibitory modulator of baroreflex function. If so, the pressor response to systemic administration of a HO inhibitor may result from decreased activity of antihypertensive mechanisms mediated by CO acting centrally as well as in the peripheral vasculature.
The view that the heme-HO system contributes to antihypertensive mechanisms received support from studies on the effect of HO substrates and inducers on blood pressure. Treatment of young spontaneously hypertensive rats with HO-1 inducers SnCl 2 , 42 heme arginate, 43 or hemin 44 lowered blood pressure, increased HO activity in kidney, and decreased the renal activity of cytochrome P450 oxygenases that synthesize vasoactive eicosanoids. Acute administration of HO substrates decreased blood pressure in spontaneously hypertensive rats, rats with deoxycorticosterone salt-induced hypertension, and rats made hypertensive by acute infusion of phenylephrine. 45 Chronic treatment with a HO substrate normalized blood pressure in rats with angiotensin II-induced hypertension and, most important, attenuated the proteinuria along with the deterioration of renal function. 46 The vasodepressor effect of HO substrates and inducers in hypertensive settings was prevented by HO inhibitors, [42] [43] [44] [45] [46] and thus it may be attributed to increased activity of antihypertensive mechanisms mediated by one or more HO product including CO. 45 It may also reflect decreased activity of pressor mechanisms mediated by cytochrome P450 eicosanoids, [42] [43] [44] the synthesis of which is impaired by CO directly, 7 and by limited availability of heme for manufacture of cytochrome P450 oxygenase. [42] [43] [44] It is of interest that neither HO substrates 45 nor inducers 42 affected blood pressure in normotensive rats, implying that this mechanism of blood pressure regulation is maximally active in normotensive animals.
Conclusion
Arterial vessels express one or more HO isoenzymes, which catalyze the metabolism of heme to CO and biliverdin. Carbon monoxide promotes vasorelaxation through mechanisms that involve activation of soluble guanylate cyclase, stimulation of calcium-activated potassium channels, or diminished synthesis of constrictor mediators, such as, endothelin and 20-HETE. Inhibitors of HO elicit vasoconstriction in vivo and in isolated pressurized arterioles. Inhibitors of HO also enhance myogenic vasoconstriction, as well as phenylephrine-induced vascular contraction. The blood pressure of awake rats is increased by acute treatment with HO inhibitors, a response that is accompanied by attenuation of baroreflex activity. All in all, it would appear that a product of HO activity manufactured by arterial vessels, CO presumably, promotes vasodilation and decreases the reactivity of vascular smooth muscle to myogenic stimuli and constrictor agonists. In doing so, CO of vascular origin may contribute to the implementation of antihypertensive mechanisms. Carbon monoxide produced in central nervous system structures, for example, the NTS, also appears to support a blood pressure-lowering mechanism linked to inhibitory modulation of baroreceptor reflex activity. Due to space limitations, this review gives inadequate consideration to HO products other than CO, such as, biliverdin, which because of its antioxidative activity also could impact on vascular functions, particularly in pathologic settings that favor oxidative stress.
